C3 Glomerulopathy

Nephrology
3
Pipeline Programs
3
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
3 programs
1
LNP023Phase 31 trial
Home Reported Outcomes in C3G StudyN/A1 trial
IptacopanN/A1 trial
Active Trials
NCT07029542Recruiting100Est. Apr 2026
NCT07331259Not Yet Recruiting83Est. Mar 2027
NCT03955445Recruiting225Est. May 2036
Arrowhead Pharmaceuticals
1 program
1
ARO-C3Phase 1/21 trial
Active Trials
NCT05083364Completed62Est. Oct 2025
NovelMed Therapeutics
NovelMed TherapeuticsOH - Cleveland
1 program
1
NM8074Phase 1/21 trial
Active Trials
NCT05647811Not Yet RecruitingEst. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisLNP023
NovelMed TherapeuticsNM8074
Arrowhead PharmaceuticalsARO-C3
NovartisIptacopan
NovartisHome Reported Outcomes in C3G Study

Clinical Trials (5)

Total enrollment: 470 patients across 5 trials

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Start: Oct 2019Est. completion: May 2036225 patients
Phase 3Recruiting

Study of NM8074 in Adult C3 Glomerulopathy Patients

Start: Nov 2025Est. completion: Jul 2027
Phase 1/2Not Yet Recruiting

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Start: Feb 2022Est. completion: Oct 202562 patients
Phase 1/2Completed

CHART-C3G/CLNP023B12011

Start: Jan 2026Est. completion: Mar 202783 patients
N/ANot Yet Recruiting
NCT07029542NovartisHome Reported Outcomes in C3G Study

Home Reported Outcomes in C3G Study

Start: Apr 2025Est. completion: Apr 2026100 patients
N/ARecruiting

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 470 patients
3 companies competing in this space